

## Confirmed Speakers

### Award & Prize Lectures

#### **PROUS INSTITUTE-OVERTON AND MEYER AWARD FOR NEW TECHNOLOGIES IN DRUG DISCOVERY** **Activity-Based Proteomics - Protein and Ligand Discovery on a Global Scale**



Prof. Benjamin CRAVATT  
(THE SCRIPPS RESEARCH INSTITUTE, La Jolla, United States)

#### **NAUTA AWARD FOR PHARMACOCHEMISTRY** **Tools and Drugs for Purine Targets - Important Players in Inflammation and Cancer**



Prof. Christa MÜLLER  
(UNIVERSITY OF BONN, Bonn, Germany)

#### **UCB-EHRLICH AWARD FOR EXCELLENCE IN MEDICINAL CHEMISTRY** **How Best to Discover Bioactive Small Molecules?**



Prof. Adam NELSON  
(UNIVERSITY OF LEEDS, Leeds, United Kingdom)

### Plenary Lectures

#### **The Therapeutic Challenge of the New Era: Developing and Making Available Life Changing Treatment to Patients with Rare Diseases**



Dr Diego ARDIGO  
(CHIESI GROUP, PARMA, Italy)

#### **Zika Virus: An Old Virus with a New Face**



Prof. Tatjana AVSIC-ZUPANC  
(UNIVERSITY OF LJUBLJANA, Ljubljana, Slovenia)

#### **Sugars & Proteins: Glycomimetics to Target Infectious Disease**



Prof. Benjamin DAVIS  
(OXFORD UNIVERSITY, Oxford, United Kingdom)

#### **It's a Small-Molecule World: Medicinal Chemistry Challenges and Opportunities for the Next Decade**



Dr Bayard HUCK  
(MERCK BIOPHARMA, Darmstadt, Germany)

#### **Smart Chemical Probes: from Bromodomain Ligands to Natural Products**

## Confirmed Speakers



Prof. Cristina NEVADO  
(UNIVERSITY OF ZURICH, Zurich, Switzerland)

### **Development of Non-Nucleosidic Compounds against DNA Viruses of the Herpes Group. The Era After Nucleosides: Letemovir and Pritelivir**



Dr Helga RÜBSAMEN-SCHAEFF  
(AICURIS GMBH & CO. KG, Wuppertal, Germany)

### **Synthetic Glycoconjugate Vaccines against Bacterial Infections**



Prof. Peter H. SEEBERGER  
(MAX PLANCK INSTITUTE OF COLLOIDS AND INTERFACES, Berlin, Germany)

## Invited Speakers

### **Intracellular DNA Sensing in Health and Disease**



Prof. Andrea ABLASSER  
(EPFL, Lausanne, Switzerland)

### **Beyond Single-Target Activities: Using Polypharmacology and Systems Readouts for Compound Selection and Mode-of-Action Analysis**



Prof. Andreas BENDER  
(UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom)

### **Stuck in a Rut with Old Chemistry**



Dr Jonas BOSTRÖM  
(ASTRAZENECA, Mölndal, Sweden)

### **In silico Polypolarmacology**



Dr Giovanni BOTTEGONI  
(HEPTARES THERAPEUTICS, Welwyn Garden City, United Kingdom)

### **Use of Cyclic Dinucleotides (CDNs) to Induce Stimulator of Interferon Genes (STING)-Dependent Antitumor Immunity**



Dr Cedric BOULARAN  
(INVIVOGEN, Toulouse, France)

### **Towards the Development of Novel Inhibitors for Chikungunya Virus Infection: Approaches in Structure-Activity-Metabolism Relationship (SAMR) Studies**

## Confirmed Speakers



Prof. Christina CHAI  
(NATIONAL UNIVERSITY OF SINGAPORE, Singapore, Singapore)

### **Targeting 'Undruggable' Transcription and Translation Factors for Degradation with Low Molecular Weight Cereblon Modulators**



Dr Philip CHAMBERLAIN  
(CELGENE, Alameda, United States)

### **"Micro-Pharmacokinetics": How Local Drug Concentration Influences Observed Binding Kinetics**



Prof. Steven CHARLTON  
(UNIVERSITY OF NOTTINGHAM, Nottingham, United Kingdom)

### **Asymmetric Synthesis of Statin API as the Hypolipidemic Agents: The Evolution from the Chemical Kinetic Resolution to the Asymmetric Catalytic Technology (An Odyssey)**



Prof. Fener CHEN  
(FUDAN UNIVERSITY, Shanghai Shi, China)

### **Modification of Cyclic Dinucleotides to Enhance Modulation of the Innate Immune Response**



Dr Diane COE  
(GLAXOSMITHKLINE, Stevenage, United Kingdom)

### **Target Binding Kinetics and its Relevance in the in vivo Context**



Dr Liesbeth DE LANGE  
(UNIVERSITY OF LEIDEN, Leiden, The Netherlands)

### **Unravelling the Mysteries of the Sphinx: Novel Targets and Small-Molecule Therapeutics from the Sphingolipid Synthesis and Signaling Pathway**



Prof. Bernard FLYNN  
(MONASH UNIVERSITY, Parkville, Australia)

### **Capturing Biological Activity in Natural Product Fragments by Chemical Synthesis**



Prof. Karl GADEMANN  
(UNIVERSITY OF ZÜRICH, Zürich, Switzerland)

### **PET Molecular Imaging – an Overview**



Prof. Antony GEE  
(KING'S COLLEGE LONDON, London, United Kingdom)

## Confirmed Speakers

### First Time Disclosure of BI 409306, a First in Class PDE9 Inhibitor for the Treatment of CNS Diseases



Dr Riccardo GIOVANNINI  
(BOEHRINGER INGELHEIM, Biberach, Germany)

### Nonpeptidic Selective Inhibitors of Immunoproteasome



Prof. Stanislav GOBEC  
(UNIVERSITY OF LJUBLJANA, Ljubljana, Slovenia)

### Novel Hybrid Macrocyclic Modalities for Structure-Based Protein Mimetics



Dr Stephanie GUERET  
(ASTRAZENECA-MAX PLANCK INSTITUTE SATELLITE UNIT, Dortmund, Germany)

### Discovery of a Novel Oral NO- and Heme-Independent sGC Activator BAY 1101042



Dr Michael G. HAHN  
(BAYER HEALTHCARE, Wuppertal, Germany)

### Allosteric Modulation of the mGlu2 Receptor: from Structure-Kinetic Relationships to in vivo Efficacy (2017 MedChemComm Emerging Investigator Lectureship)



Dr Laura HEITMAN  
(UNIVERSITY OF LEIDEN, Leiden, The Netherlands)

### Breaking the Limits in Analyzing Carbohydrate Recognition by NMR



Dr Jesus JIMENEZ-BARBERO  
(CIC BIOGUNE, Derio, Spain)

### Tankyrase Inhibitor Development: Evidence for Potential in Cancer Immune Therapy

Prof. Stefan KRAUSS  
(UNIVERSITY OF OSLO, Oslo, Norway)

### The Discovery of Semaglutide - A Journey from Ala Scan to Structural Design of GLP-1 Analogues



Dr Jesper LAU  
(NOVO NORDISK, Maaloev, Denmark)

### EGFR Triple Mutant L858R\_T790M\_C797S Recent Set-Backs and New Hope in Fighting Mutant Non-Small Cell Lung Cancer



Prof. Stefan LAUFER  
(UNIVERSITY OF TÜBINGEN, Tübingen, Germany)

### Artificial Intelligence. Not Just Another Name for in Silico Design

## Confirmed Speakers



Dr David E. LEAHY  
(THE DISCOVERY BUS LTD, Macclesfield, United Kingdom)

### **Multi-Functional Treatments for Multi-Factorial Neurodegenerative Disorders: the Challenge of Alzheimer's Disease**



Dr Mark J. MILLAN  
(INSTITUT DE RECHERCHES SERVIER, Croissy-sur-Seine, France)

### **A Multidisciplinary Strategy to Synthetic Carbohydrate-Based Conjugates for Vaccination against Shigella: from Concept to First-in-Human Study**



Dr Laurence MULARD  
(PASTEUR INSTITUTE, Paris, France)

### **Recent Advances in Bifunctional Degradable Molecules (e.g. SNIPER) for Targeted Protein Degradation via the Ubiquitin Proteasome System; Status and Outlook**



Dr Mikihiro NAITO  
(NATIONAL INSTITUTE OF HEALTH SCIENCES, Tokyo, Japan)

### **Activity-Based Glycosidase Profiling in Biomedicine and Biotechnology**



Prof. Hermen OVERKLEEF  
(LEIDEN UNIVERSITY, Leiden, The Netherlands)

### **Obeticholic Acid, Leading in the NASH Race. History and Perspectives**



Prof. Roberto PELLICCIARI  
(TES PHARMA SRL, Corciano, Italy)

### **Discovery of LOU064, a Covalent BTK Inhibitor with Best in Class Selectivity**



Dr Robert PULZ  
(NOVARTIS PHARMA, Basel, Switzerland)

### **Synthesis and Fungicidal Activity of a New Family of Oxysterol Binding Protein Inhibitors**



Dr Laura QUARANTA  
(SYNGENTA AG, Basel, Switzerland)

### **Small Molecule Immune Checkpoint Antagonists for Cancer Therapy**



Dr Murali RAMACHANDRA  
(AURIGENE DISCOVERY TECHNOLOGIES LTD, Bangalore, India)

## Confirmed Speakers

### Discovery of RG7916, a Selective SMN2 Splicing Modifier for the Treatment of Spinal Muscular Atrophy



Dr Hasane RATNI  
(F. HOFFMANN-LA ROCHE LTD, Basel, Switzerland)

### Natural Products as Leads in Agrochemistry



Dr Joachim RHEINHEIMER  
(BASF, Ludwigshafen am Rhein, Germany)

### An Iron Hand over Cancer Stem Cells



Dr Raphaël RODRIGUEZ  
(INSTITUT CURIE, Paris, France)

### Controlling Sphingosine-1-Phosphate Levels as a Therapeutic Strategy



Dr Webster L. SANTOS  
(VIRGINIA TECH, Blacksburg, United States)

### Design and Rationale for Exquisite Selectivity of Preclinical and Clinical Kinase Inhibitors



Dr Laurent SCHIO  
(SANOFI, Vitry sur Seine, France)

### PET in Neuroscience Drug Discovery and Development



Dr Magnus SCHOU  
(KAROLINSKA INSTITUTE, Stockholm, Sweden)

### Computer-Aided Synthesis Planning



Mr Marwin SEGLER  
(BENEVOLENTAI, London, United Kingdom)

### C-Natriuretic Peptide Agonists for Cardiovascular Disease



Prof. David SELWOOD  
(UNIVERSITY COLLEGE LONDON, London, United Kingdom)

### Design and Synthesis of Congeners of Cyclic ADP-Ribose, a Ca<sup>2+</sup>-Mobilizing Second Messenger, Toward Identification of the Target Protein



Prof. Satoshi SHUTO  
(HOKKAIDO UNIVERSITY, Sapporo, Japan)

## Confirmed Speakers

### Design, Synthesis, and Mechanism of $\beta$ -Glucocerebrosidase Activators for Gaucher's and Parkinson's Diseases



Prof. Richard B. SILVERMAN  
(NORTHWESTERN UNIVERSITY, Evanston, United States)

### New Chemical Libraries in Exploration of Chemical Space



Prof. Jurij SVETE  
(UNIVERSITY OF LJUBLJANA, Ljubljana, Slovenia)

### Cell Permeability with Beyond 'Rule of 5' Modalities – Do We Understand How This Works?



Dr Nick TERRETT  
(MERCK SHARP & DOHME RESEARCH GMBH (MSD), Kriens, Switzerland)

### In vivo Anti-Viral and -Tumor Effect Of 3'3'-cAIMP STING Activation



Dr Martin K. THOMSEN  
(AARHUS UNIVERSITY, Aarhus C, Denmark)

### The Zinc-Degrome



Dr Nicolas THOMÄ  
(FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH, Basel, Switzerland)

### Discovery of JNJ-64619178 as a Potent and Selective PRMT5 Inhibitor for the Treatment of Lung and Hematologic Cancers



Dr Jan Willem THURING  
(JANSSEN PHARMACEUTICA NV, Beerse, Belgium)

### Tricyclic Peptides via Templated Tandem CLIPS/CUAAC Cyclizations



Prof. Peter TIMMERMAN  
(PEPSCAN THERAPEUTICS, Lelystad, The Netherlands)

### All Bugs are Shallow: Open Source Drug Discovery



Prof. Matthew TODD  
(UNIVERSITY COLLEGE LONDON, London, United Kingdom)

### Targeting the Monomeric Intrinsically Disordered Structural State of Tau and Alpha-Synuclein by Small Molecules as a Potential Therapeutic Strategy for Alzheimer's and Parkinson's Disease



## Confirmed Speakers



Dr Gergely TOTH  
(CANTABIO PHARMACEUTICALS INC., Sunnyvale, United States)

### Cyclic Dinucleotide STING Agonists as Anti-Tumor Agents



Dr Wes TROTTER  
(MSD, Boston, United States)

### Discovery of LJN452 (Tropifexor), a Highly Potent, Non-Bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and NASH



Dr David TULLY  
(NOVARTIS, Emeryville, United States)

### Positive Allosteric Modulators of the GABA-B Receptor



Dr Sean C. TURNER  
(ABBVIE, Ludwigshafen am Rhein, Germany)

### The Value of Orthogonal Techniques for Elucidating Binding Site(s) of GPCR Allosteric Modulators: a Case Study With Positive Allosteric Modulators of Dopamine Receptors



Dr Anne VALADE  
(UCB, Braine-l'Alleud, Belgium)

### New Modalities for Complex and Unprecedented Biological Targets



Dr Eric VALEUR  
(ASTRAZENECA, IMED BIOTECH UNIT, Cambridge, United States)

### Re-Energising Small Molecule Drug Discovery



Dr Willem VAN HOORN  
(EXSCIENTIA, Dundee, United Kingdom)

### Synthesis of MedChem-Relevant Gem-Difluorocycloalkane Building Blocks



Prof. Dmytro VOLOCHNYUK  
(ENAMINE LTD, Kyiv, Ukraine)

### A New Target in Fungal Protein Biosynthesis: Shared Learnings for AgChem and MedChem



Dr Franz VON NUSSBAUM  
(BAYER AG, Berlin, Germany)

### Targeting of Cancer Specific Glycopeptide Epitopes



## Confirmed Speakers



Prof. Hans WANDALL  
(UNIVERSITY OF COPENHAGEN, Copenhagen, Denmark)

### Active Site Inhibitors of Sphingosine 1-Phosphate Lyase - Exploring Novel Biology with Tool Compounds



Dr Sven WEILER  
(BASILEA PHARMACEUTICA INTERNATIONAL LTD., Basel, Switzerland)

### PET for Oncology Drug Discovery and Development



Prof. Bert WINDHORST  
(VU UNIVERSITY MEDICAL CENTER, Amsterdam, The Netherlands)

### Discovery of Peptidomimetics Targeting Protein-Protein Interactions of Alpha-Synuclein



Dr Wolfgang WRASIDLO  
(UNIVERSITY OF CALIFORNIA SAN DIEGO, La Jolla, United States)

### Small Molecule Immunomodulators that Target Toll-Like Receptors



Prof. Hang YIN  
(TSINGHUA UNIVERSITY, Beijing, China)

### Practical Asymmetric Hydrogenation



Prof. Xumu ZHANG  
(SOUTHERN UNIVERSITY OF SCIENCE AND TECHNOLOGY, Guangdong, China)

### Understanding Aggregation Inhibition of Alpha-Synuclein and Tau by Small Molecules



Prof. Markus ZWECKSTETTER  
(MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY, Göttingen, Germany)

## Oral Communications

### Discovery and Clinical Evaluation of MK-8150, a Novel Nitric Oxide Donor with a Unique Mechanism of Nitric Oxide Release



Dr Amjad ALI  
(MERCK & CO. INC., Kenilworth, United States)

### Brain-Penetrant Autophagy Modulators for Treating Neurodegenerative Diseases

## Confirmed Speakers



Dr Steve ANDREWS  
(UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom)

**Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 that Enables Transient Target Engagement for the Treatment of Haematological Malignancies**



Dr Bernard BARLAAM  
(ASTRAZENECA, Cambridge, United Kingdom)

**First Disclosure of the Clinical Candidate BAY-840, a Potent And Selective hBradykinin B1 Antagonist for the Treatment of Chronic Inflammatory Diseases, Generated within the Bayer-Evotec Strategic Alliance**



Dr Stefan BÄURLE  
(BAYER AG, Berlin, Germany)

**Metabotropic Glutamate Receptor Type 2 Positive Allosteric Modulators (mGlu2 Receptor PAMS) as a Transformational Epilepsy Treatment**



Dr Jose CID  
(JANSSEN R&D, Toledo, Spain)

**Targeting Non Essential Bacterial Targets as a Novel Route to Counteract Bacterial Resistance**



Prof. Gabriele COSTANTINO  
(UNIVERSITY OF PARMA, Parma, Italy)

**EFMC Prize for a Young Medicinal Chemist in Industry  
The Challenges of Restoring Programmed Cell Death Through MCL1 Inhibition**



Dr Marton CSEKEI  
(SERVIER RESEARCH INSTITUTE OF MEDICINAL CHEMISTRY, Budapest, Hungary)

**Discovery of Candidates for PET Molecular Imaging of Pathological TDP-43 Aggregates in Frontotemporal Dementia and Amyotrophic Lateral Sclerosis Patients**



Dr Vincent DARMENCY  
(AC IMMUNE SA, Lausanne, Switzerland)

**New Small-Molecule Immune Checkpoint Inhibitors: A Step Forward in Cancer Immunotherapy**



Ms Ana Rita DE CARVALHO ACURCIO  
(UNIVERSITY OF LISBON, Lisbon, Portugal)

**Potency and Patents, New Arenas for Matched Molecular Pair Analysis in the AI World**

## Confirmed Speakers



Dr AI DOSSETTER  
(MEDCHEMICA LIMITED, Macclesfield, United Kingdom)

### **Synthetic Small-Molecule RNA Ligands: Scope and Therapeutic Applications**



Dr Maria DUCA  
(UNIVERSITÉ CÔTE D'AZUR, Nice, France)

### **Chemical Probes for New Therapeutic Concept Discovery**



Dr Peter ETTMAYER  
(BOEHRINGER-INGELHEIM, Vienna, Austria)

### **Identification of New Antimalarial GSK607: An Example of Adaptive and Differentiated Early Drug Development**



Dr Esther FERNANDEZ  
(GLAXOSMITHKLINE, Tres Cantos, Spain)

### **Development of Potent, Selective, CNS Penetrant Small Molecule Inhibitors of Notum to Potentiate Wnt Signaling for the Maintenance of Synaptic Function in Alzheimer's Disease**



Prof. Paul FISH  
(ARUK UCL DRUG DISCOVERY INSTITUTE, London, United Kingdom)

### **Drugging the Fbw7 E3 Ligase with a Combined Computational and Biophysical Approach**



Dr Carles GALDEANO  
(UNIVERSITY OF BARCELONA, Barcelona, Spain)

### **Buruli Ulcer and the mTOR Pathway: Total Synthesis, Structure-Activity and Target Elucidation Studies of Mycolactones**



Dr Matthias GEHRINGER  
(UNIVERSITY OF TUEBINGEN, Tuebingen, Germany)

### **Large-Scale Analysis of Kinase Inhibitors' Target Binding Kinetics and its Implications for Drug Discovery**



Ms Victoria GEORGI  
(BAYER AG, Berlin, Germany)

### **Discovery of the TYK2 Selective Inhibitor PF-6826647 for the Treatment of Crohn's Disease, and Other Autoimmune Conditions**

## Confirmed Speakers



Dr Brian GERSTENBERGER  
(PFIZER, Cambridge, United States)

### **Integrated System for the Expedited Generation and Characterization of Drug-Like Libraries for Hit-to-Lead Explorations**



Prof. Antimo GIOIELLO  
(UNIVERSITY OF PERUGIA, Perugia, Italy)

### **IUPAC-Richter Prize Lecture Discovery of CFTR Modulators For The Treatment of Cystic Fibrosis**



Dr Peter GROOTENHUIS  
(VERTEX PHARMACEUTICALS, San Diego, United States)

### **ASTX660, the First Fragment-Derived IAP Antagonist in the Clinic**



Dr Steven HOWARD  
(ASTEX THERAPEUTICS , Cambridge , United Kingdom)

### **Glycoside Antagonists of Bacterial Lectins: New Treatment Options for Recurrent and Antibiotic Resistant UTI**



Prof. James JANETKA  
(WASHINGTON UNIVERSITY IN SAINT LOUIS, Saint Louis, United States)

### **Discovery of First-in Class, Selective and Noncovalent Small Molecule Inhibitors of DNMT1**



Dr Allan JORDAN  
(CANCER RESEARCH UK MANCHESTER INSTITUTE, Manchester, United Kingdom)

### **Discovery of GDC-0077: A Highly Selective Inhibitor and Degradator of Mutant PI3K-Alpha**



Dr Jamie KNIGHT  
(CHARLES RIVER, Harlow, United Kingdom)

### **The Discovery of CNP520, an Amino-1,4-Oxazine BACE Inhibitor in Prevention Studies**



Dr Rainer MACHAUER  
(NOVARTIS PHARMA AG, Basel, Switzerland)

### **A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase to Treat Non-Alcoholic Steatohepatitis (EFMC-YMCS Presentation Prize)**

## Confirmed Speakers



Dr Daniel MERK  
(ETH ZÜRICH, Zürich, Switzerland)

### Development of Small-Molecule Inhibitors of Adipose Triglyceride Lipase (ATGL)



Ms Anna MIGGLAUTSCH  
(TU GRAZ, Graz, Austria)

### Development of Novel Sialyltransferase Inhibitors via Computer Aided Drug Design



Mr Andrew MONTGOMERY  
(UNIVERSITY OF WOLLONGONG, Wollongong, Australia)

### Small-Molecule Stabilization of Protein-Protein Interactions by Natural Products, Supramolecular Ligands, Fragments and Macrocycles



Dr Christian OTTMANN  
(EINDHOVEN UNIVERSITY OF TECHNOLOGY, Eindhoven, The Netherlands)

### AMPA Receptor Positive Allosteric Modulators Based on New Scaffolds: Design, Synthesis, and Studies



Dr Vladimir A. PALYULIN  
(LOMONOSOV MOSCOW STATE UNIVERSITY, Moscow, Russia)

### Charting the Structure-Resistance Landscape of Novel Antibiotics



Mr Tamas REVESZ  
(BIOLOGICAL RESEARCH CENTRE, HUNGARIAN ACADEMY OF SCIENCES, Szeged, Hungary)

### Small Molecules Inhibiting PD1-PDL1 Immune Checkpoint



Dr Shabnam SHAABANI  
(UNIVERSITY OF GRONINGEN, Groningen, The Netherlands)

### Anti-HBV Drug Discovery Enabled by Structure-Based Drug Design and Phenotypic Screening



Dr Hong SHEN  
(ROCHE INNOVATION CENTER, Shanghai, China)

### Mechanisms of HIV-1 Nucleocapsid Protein Inhibition by Small Molecules Targeting RNA



Dr Alice SOSIC  
(UNIVERSITY OF PADOVA, Padova, Italy)

## Confirmed Speakers

### **Discovery and Optimization of Non-Covalent, Selective, and Bioavailable Small Molecule Inhibitors of the KEAP1-Nrf2 Pathway**



Dr Hauke SZILLAT  
(SANOFI, Frankfurt, Germany)

### **EFMC Prize for a Young Medicinal Chemist in Academia Carbohydrate-binding Proteins as Targets for Anti-Infectives and Diagnostics: ESKAPE pathogen Pseudomonas aeruginosa and its Lectins**



Dr Alexander TITZ  
(HELMHOLTZ INSTITUTE FOR PHARMACEUTICAL SCIENCES, Saarbrücken, Germany)

### **Discovery of SPL-707: A Potent, Selective, and Orally Bioavailable SPPL2a Inhibitor**



Dr Juraj VELCICKY  
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland)

### **The First Class of Orally Available Mono-Saccharide Galectin-3 Inhibitors for Treatment of Fibrosis (NASH) and Cancer**



Dr Fredrik ZETTERBERG  
(GALECTO BIOTECH, Gothenburg, Sweden)